Ariad Pharmaceuticals, Inc. Reports First Quarter 2013 Financial Results and Development Progress

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial results for the first quarter, including revenue from its first cancer medicine, Iclusig® (ponatinib), which was approved last December by the U.S. Food & Drug Administration. The Company also provided an update on corporate developments.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC